Vaccine against black fever being tested
April 23, 2012 By Sandi Doughton in Medications
After more than two decades of research, scientists are testing the first vaccine against the deadliest form of a disease that infects more than 12 million people worldwide.
Called leishmaniasis, or black fever, the parasitic infection is transmitted by the bite of no-see-um-sized sand flies, whose range appears to be expanding - including in the United States. But if the vaccine proves effective, it will be most valuable in India, Bangladesh, Brazil and the handful of other countries where the virulent version is most prevalent.
Three dozen volunteers in Tacoma, Wash., are rolling up their sleeves for the first shots, as part of a clinical trial to ensure that the vaccine is safe. Results so far are promising, but it will be months before the final data are in, said Dr. Franco Piazza, medical director for the Infectious Disease Research Institute or IDRI. Researchers at the Seattle nonprofit are seeking vaccines and cures for several neglected diseases, but black fever is the one they've worked on longest.
The vaccine's safety will also be tested in India, starting late this year. If it passes those hurdles, the drug will then get a larger-scale test in India to see how well it protects people from the disease.
The work is funded by the Bill & Melinda Gates Foundation.
"It's early days," cautioned IDRI founder Dr. Steve Reed, who for many years waged a lonely battle against a disease few Americans have ever heard of - or can pronounce. (It's leash-muh-nye-uh-sis.) Reed's quest got a huge boost when the Gates Foundation took up the cause, funneling $54 million to IDRI's leishmaniasis research.
Now, if everything goes well, Reed is optimistic the new vaccine could be ready for market in about five years.
The disease comes in many forms, one of which attacks the skin, causing painful lesions that are slow to heal and leave disfiguring scars. "People get so desperate they want to kill themselves," said Reed, who spent five years working with patients in Brazil.
American troops serving in Iraq and Afghanistan have been plagued by what they call "Baghdad Boil." A few returning veterans sought treatment for the sores at the Veterans Affairs Puget Sound Health Care System, said Dr. Richard Miller, chief of infectious disease.
Reed and his colleagues developed an earlier vaccine to protect against the skin infection, which is rarely fatal.
But the Gates Foundation decided to focus its funding on the disease's most dangerous manifestation, said Dr. Jan Agosti, foundation program officer. In the form called visceral leishmaniasis, which the new IDRI vaccine is designed to fight, parasites attack the liver, spleen and bone marrow.
Sometimes called the parasitic version of AIDS, the infection is aggravated by the bug's ability to hide inside the white blood cells that would normally engulf the invaders. Victims suffer from anemia, fever and a weakened immune system that leaves them vulnerable to other infections. Pigments from ruptured blood cells can turn the skin dark, hence the name "black fever."
The World Health Organization estimates nearly half a million people contract black fever every year, and more than 10 percent will die.
People with chronic infections are unable to work or care for their families. "For every death you see, there are at least 10 people who have it," Reed said. "There's a lot of suffering that's not reflected in the numbers."
Treatments exist, but most have serious side effects or aren't accessible to the world's poor. Drug resistance is also rising.
IDRI partnered with an Indian pharmaceutical company to manufacture the vaccine for clinical trials in Asia and for commercial distribution. India has more cases than any other country, and it's important to keep the cost of the vaccine low so it can reach the poorest people who need it most, Agosti said.
Leishmaniasis is rare in the United States. Until recently, the only contracted cases here were in south-central Texas. Then infections started popping up in the northern part of the state.
Globally, the World Health Organization says the disease is spreading as a result of deforestation, irrigation and dam building that expand habitat for sand flies. Climate change may also be a factor. If warming continues, one analysis warns, sand flies in the United States could expand their range as far north as the Canadian border.
(c)2012 The Seattle Times
Distributed by MCT Information Services
-
First vaccine against fatal visceral leishmaniasis enters clinical trial
Feb 23, 2012 |
not rated yet |
0
-
First TB vaccine booster unveiled by Seattle scientists
Oct 14, 2010 |
not rated yet |
0
-
Troops in Iraq fight bugs, parasites
May 07, 2007 |
not rated yet |
0
-
A novel oral treatment for leishmaniasis has potential to save thousands of lives
Oct 24, 2011 |
not rated yet |
0
-
Infectious skin disease found in Texas
Sep 16, 2007 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
15 hours ago
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
1 hour ago |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
2 hours ago |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
May 22, 2013 |
not rated yet |
0
Statin use is linked to increased risk of developing diabetes, warn researchers
Treatment with high potency statins (especially atorvastatin and simvastatin) may increase the risk of developing diabetes, suggests a paper published today in BMJ.
Consumers largely underestimating calorie content of fast food
People eating at fast food restaurants largely underestimate the calorie content of meals, especially large ones, according to a paper published today in BMJ.
Dual-source cardiac CT IDs CAD in hard-to-image patients
(HealthDay)—In patients who have previously been considered difficult to image, dual-source cardiac (DSC) computed tomography (CT) can identify clinically significant coronary artery disease, according ...
Glucosamine supplements tied to risk of eye condition
(HealthDay)—Glucosamine supplements that millions of Americans take to help treat hip and knee osteoarthritis may have an unexpected side effect: They may increase risk for developing glaucoma, a small ...
Controlling mood through the motions of mitochondria
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
WHO: Scientific red tape mars efforts vs. virus
International efforts to combat a new pneumonia-like virus that has now killed 22 people are being slowed by unclear rules and competition for the potentially profitable rights to disease samples, the head ...